127.32USD-0.73%Mkt Cap: —P/E: —1d ago
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory …
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value27.25B $
Revenue (TTM)1.14B $
Gross Profit949.42M $
Net Income (TTM)-875.31M $
Revenue/Share5.299 USD
Last Price127.32 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.7K
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-34.28
EV/Revenue23.96
P/S—
P/B36.37
EPS (TTM)-3.78
EPS (Forward)—
52W Range
125.0031% of range132.40
52W High132.40 USD
52W Low125.00 USD
Profitability
Gross Margin83.45%
Oper. Margin-23.81%
EBITDA Margin-69.88%
Profit Margin-76.94%
ROE-87.22%
ROA-22.17%
Growth
Revenue Growth296.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-778.92M $
CapEx (TTM)—
FCF Margin-50.26%
FCF Yield—
Net Debt-420.59M $
Net Debt/EBITDA0.53
Balance Sheet
Debt/Equity97.65
Current Ratio3.72
Quick Ratio3.13
Book Value/Sh3.470 USD
Cash/Share5.313 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.77.09M
Float216.86M
Insiders0.51%
Institutions104.85%
Technical
SMA 5028.37 (+348.7%)
SMA 20024.95 (+410.3%)
Beta0.79
S&P 52W Chg18.16%
Avg Vol (30d)1.13K
Avg Vol (10d)254
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—